May 6th 2024
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Nivolumab With Sunitinib or Pazopanib Proves Too Toxic in Early RCC Trial
December 21st 2018Treatment with the immune checkpoint inhibitor nivolumab demonstrated dose-limiting toxicities when combined with the tyrosine kinase inhibitors sunitinib or pazopanib to treat advanced or metastatic renal cell carcinoma, according to the results of a phase I parallel cohort dose escalation trial. However, both combinations showed encouraging preliminary antitumor activity.
Read More
Antibiotics Reduce ICI Efficacy for Patients With Urological Cancers
November 30th 2018Patients with metastatic renal and urothelial bladder cancer who receive antibiotics concomitantly with immune checkpoint inhibitors have shorter progression-free survival and overall survival rates than patients who do not, according to a poster presented at the European Congress on Immunotherapies in Cancer™ conference, hosted by Physicians’ Education Resource®, LLC, September 21 and 22, 2018, in Barcelona, Spain.
Read More
Selecting I-O Agents and Combinations for Patients With RCC
November 27th 2018Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the considerations behind selecting an immune-oncology agent for the treatment of patients with renal cell carcinoma.
Watch
CHMP Recommends Nivolumab Plus Ipilimumab Combo for Frontline RCC
November 19th 2018Nivolumab in combination with low-dose ipilimumab has been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use as treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma in the frontline setting, according to Bristol-Meyers Squibb, the developer of both immunotherapy agents.
Read More
Gene Expression Data Validated for Treatment Benefit in RCC
November 14th 2018Distinct subgroups of patients with renal cell carcinoma defined by gene expression signatures were correlated with improved progression-free survival with immunotherapy or a targeted agent, an analysis of the phase II IMmotion151 trial showed.<br />
Read More
PFS Improved With Tivozanib in Highly Refractory RCC
November 8th 2018According to topline findings from the phase III TIVO-3 trial, tivozanib (Fotivda) reduced the risk of disease progression or death by 26% compared with sorafenib (Nexavar) in patients with highly refractory advanced or metastatic renal cell carcinoma.
Read More
Immunotherapy/TKI Combinations in Advanced RCC
November 8th 2018Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the potential for immunotherapy/TKI combinations in the treatment of advanced renal cell carcinoma.
Watch
Expert Highlights Efficacy of Avelumab in Early Lines of Therapy for Advanced RCC
October 26th 2018Ulka Vaishampayan, MD, discussed the data reported from the phase Ib JAVELIN Solid Tumor trial at the ESMO 2018 Congress and addressed how these data will affect the treatment landscape for patients with advanced RCC.
Read More
Rini Highlights Benefit With Atezolizumab/Bevacizumab Combo in Distinct Gene Signatures in RCC
October 26th 2018In an interview with <em>Targeted Oncology, </em>Brian I. Rini, MD, discussed these core findings from the IMmotion 151 trial he presented at the conference, as well as the implications of these findings in RCC moving forward.
Read More
Selecting Atezolizumab Plus Bevacizumab Versus Ipilimumab Plus Nivolumab in RCC
October 26th 2018Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma. He says atezolizumab plus bevacizumab will never be compared head to head with ipilimumab plus nivolumab.
Watch
Despite Advances, Interpreting Data From Genomics and Precision Medicine Lags
October 25th 2018I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.
Read More